Código
P110
Área Técnica
Retina
Instituição onde foi realizado o trabalho
- Principal: University of São Paulo
Autores
- THAISA SILVEIRA BARBOSA (Interesse Comercial: NÃO)
- Eduardo Ferracioli Oda (Interesse Comercial: NÃO)
- Juliana Mika Kato (Interesse Comercial: NÃO)
- Bruno Fortaleza de Aquino Ferreira (Interesse Comercial: NÃO)
- Luiza Manhezi de Freitas Oliveira (Interesse Comercial: NÃO)
- Joāo Nóbrega de Almeira Junior (Interesse Comercial: NÃO)
- Flávia Rossi (Interesse Comercial: NÃO)
- Sergio Luis Gianotti Pimentel (Interesse Comercial: NÃO)
- Joyce Hisae Yamamoto (Interesse Comercial: NÃO)
- Tatiana Tanaka (Interesse Comercial: NÃO)
Título
ACUTE ENDOPHTHALMITIS CAUSED BY STAPHYLOCOCCUS EPIDERMIDIS: A 6-YEAR ANTIMICROBIAL SUSCEPTIBILITY ANALYSIS
Objetivo
To analyze the antimicrobial sensitivity of Staphylococcus epidermidis isolated from endophthalmitis cases over the last 6 years.
Método
Cases of acute endophthalmitis attended at Hospital das Clínicas at University of Sao Paulo between January 2010 and November 2016 were included in this observational retrospective study. Aqueous humor and vitreous humor samples were collected and sent for culture. Identification and sensitivity tests were performed using an automated broth microdilution method (bioMerieux Vitek 2, Hazelwood, MO, USA). Only data from cases which S. epidermidis were isolated were analyzed.
Resultado
Seventy cases of acute endophthalmitis presented positive cultures. Eighteen (25.71%) of these were due to S. epidermidis. From 2010 to 2016, a tendency to decrease in antimicrobial susceptibilty was observed: 100% to 66.66% for clindamycin, 40% to 22.22% for oxacilin, 40% to 11.11% for ciprofloxacin and 40% to 11.11% for moxifloxacin. In contrast, sensitivity to linezolid (100%) and vancomycin (100%) remained stable along the years.
Conclusão
Moxifloxacin is a fourth-generation fluoroquinolone widely used in ophthalmology as postoperative topical antibiotic therapy. On this short series, we identified an important decrease in antimicrobial susceptibility for moxifloxacin over the last 6 years. This susceptibility is lower than reported by recent literature (3-6), however, Vancomycin remained active against S. epidermidis.